# A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses

> **NCT07330674** · PHASE1 · RECRUITING · sponsor: **Aptabio Therapeutics, Inc.** · enrollment: 68 (estimated)

## Conditions studied

- Age Related Macular Degeneration (ARMD)
- AMD - Age-Related Macular Degeneration

## Interventions

- **DRUG:** ABF-101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07330674
- **Lead sponsor:** Aptabio Therapeutics, Inc.
- **Sponsor class:** INDIV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2027-11
- **Final completion:** 2027-12
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07330674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07330674, "A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07330674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*